biote Corp. Form 8-K Summary
Business Context and Reporting Period
biote Corp. filed a Current Report on Form 8-K dated May 9, 2023. The filing furnished the company’s earnings press release for the quarter ended March 31, 2023 and announced a warrant exchange offer and related consent solicitation. The filing text provided does not include the financial results contained in Exhibit 99.1.
Financial Metrics
| Metric | Reported information |
|---|---|
| Revenue, profit, margins, and cash flow | The filing text does not provide clear values; these details are contained in the referenced earnings press release. |
| Debt and liquidity | The filing text does not provide clear values. |
| Other financial information | No additional financial metrics are included in the body of the filing. |
Material Changes Versus the Prior Comparable Period
The filing text does not provide sufficient financial information to assess changes versus the prior-year or prior-quarter comparable period.
Warrant Exchange Offer and Consent Solicitation
- Holders may exchange each outstanding warrant for 0.23 shares of Class A common stock.
- If approved, the proposed warrant amendment would allow the company to require conversion of each warrant remaining outstanding after the offer into 0.207 shares of common stock, 10% below the offer exchange ratio.
- The offer and consent solicitation commenced May 9, 2023 and were scheduled to expire one minute after 11:59 p.m. Eastern Standard Time on June 7, 2023, subject to extension.
- Approval generally requires consent from holders of at least 50% of the public warrants and, for amendments affecting private placement warrants, at least 50% of the private placement warrants.
- Parties holding approximately 19.4% of the public warrants and 59.3% of the private placement warrants agreed to tender and consent under a tender and support agreement. The filing states that, if the other offer conditions are satisfied or waived, the warrant amendment will be adopted.
Outlook, Risks, and Unusual Items
The filing contains forward-looking statements regarding future financial performance, business strategies, growth, market acceptance, and completion of the warrant transactions. Management cautions that actual results may differ materially because of risks including regulatory oversight and changes in law, competition, limited operating history, reliance on third-party manufacturing of bio-identical hormones, market acceptance of the Biote Method and dietary supplements, geographic economic conditions, intellectual property protection, expansion execution, and interest and exchange-rate changes.
The warrant exchange and consent solicitation are subject to the terms and conditions in the Prospectus/Offer to Exchange on Form S-4, Schedule TO, and related materials. Investors are directed to review those documents for complete terms, conditions, risks, and potential effects on the company’s share count and warrant obligations.
The earnings information and warrant announcements were furnished through the filing and are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference except where expressly stated.
Important Facts to Verify
- Review Exhibit 99.1 for quarterly revenue, earnings, margins, cash flow, debt, liquidity, and management guidance.
- Confirm the final terms, conditions, amendments, and expiration status of the warrant exchange offer in the Prospectus and Schedule TO.
- Verify the number of public and private placement warrants outstanding and the potential common-stock dilution under the 0.23- and 0.207-share conversion ratios.
- Confirm whether the required warrant-holder consents were obtained and whether the warrant amendment became effective.
- Assess the regulatory, manufacturing, competitive, market-acceptance, and growth risks described in the Prospectus and subsequent SEC filings.